posted numerous times ad nauseam:
TOMDF's Stable of 9 Horsies and 50 Good Reasons to Run-Away:
01. playing/sponsoring 'flag-football' is good for shareholders
02. issuing free shares to Wall St. 'has-beens' will attract new investors
03. hiring an 'x-body builder' for PR is a wise decision
04. hiring a 'kiddie influencer' is a sound decision
05. hiring a TaiBo instructor for Todos promotions is going to reverse serial dilution
06. holding photo op's w/ Michael Irvin and NYSE backdrop is good marketing strategy
07. selling 'gummy bears' is the way of the future
08. selling 'no-name' high priced vending machine products is smart
09. has 10-Bil. AS avalanche over-hang on the heads of shareholders is smart
10. has 3-Bil. In OS folks, yes that 3-BILLION shares issued folks
11. now OTC Compliant and is non-reporting
12. thinks serial diluting the shit out of existing shareholders monthly is "financial engineering"
13. issues fake "Word Salad" tweets & PR's repeatedly and non-stop
14. $5-Mil. qtrly. losses on the books and growing
15. desperate crowdfunding offering which won’t raise diddly
16. promotes Israel & Greece EAU’s - but never gets it done
17. keep saying major news is coming - but somehow it never does
18. only issue conference news like JPM and the pps goes down – mostly on ‘sell the news’ dilution
19. CEO spends all day on Twitter arguing with MD & PhD’s thinking it’s a smart idea
20. investing in failed Para Moto CV-19 mobile test labs amounting to dire financial losses
21. $50-Mil. vending machine business unable to launch due to "cash flow" shortages per CEO
22. crowdfunding financial assistance way behind with missed launch schedules & dates
23. fake spokesperson RS answering MB posts on behalf of company with ulterior motives
24. GC spends all day on Twitter - shareholders quote him thinking GC’s statements are the truth
25. the deal to sell 3-CL expired Dec 31st w/Dr. Orad - still nothing except CEO on Twitter rant
26. Provista employees snot paid, complaining on public forums – GC didn’t want to meet w/them
27. Monkey Pox test kits only made it to a public GA grammar school – where’s distribution of kits
28. Pres. Biden ends COVID Pandemic on 01/30/23 – Tollovid sales will drop bigley
29. CEO trying desperately to jump on LH-COVID wagon, but that’s a risk, as in all eggs in 1 basket
30. Lympro…? oh yeah - waiting for the ‘German’ polices list of approval before releasing the results
31. Videssa commercialized in 2023? yeah right – no Tollovid LH COVID data is very disturbing
32. just how many Tollovid bottles have been sold - when - what’s the total ROI – seems sketchy
33. just what’s happening with the purchase of the ultra-expensive Texas facility
34. Tollovid sales that have never materialized
35. monkeypox testing that’s brought in next to zero revenue
36. crowdfunding campaign that turned out to be a complete dud
37. 3CL Todos in China - GC said they’re sending samples - where exactly did they send them?
38. has 1:500 SH approved RS in filings just waiting for the right time to ‘drop the bomb’
39. Uplist in 2nd half of 2021 | we’re focused on creating SH value for our SH’s – my arse
40. TOMDF plans to launch Vedessa clinical study in 2022 in order to drive sales by 2023 my arse
41. CEO says NasDaq Uplisting 1st half of 2022, NCL Pharma acquisition of track – my arse
42. “As a result, we have our hospitalized COVID Program on pause" - say bye-bye to any EAU folks
43. Tollovir is dead - website was down for a week - dilution is through the roof.
44. Crowdfunding non-existent, botanical CBD Gummy Bears have gone nowhere
45. Employees being laid off left and right, let alone actually being paid
46. TOMDF is now PINK Delinquent non-reporting
47. dilution toxic death spiral financing will keep all TOMDF SH’s broke, you’ll NEVER get your $ out
48. GC unable to close a deal with Arad and NCL for IP rights to all things Tollo
49. Todos will now own 100% of 3CL Pharma but only has distribution rights of Tollo products in NA
50. all that TOMDF SH’s now have is distribution rights
SMH - sad but true
MOO - Happy New Year
